# Xeriant, Inc.: Form 10-Q for the period ended Dec 31, 2021

- Company: [Xeriant, Inc.](/companies/xeri.md) (CIK 1481504)
- Form: 10-Q
- Filed: 2022-02-15
- Accepted by EDGAR: Feb 15, 2022, 16:53 ET
- Period: 2021-12-31
- Accession: 0001477932-22-000865
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1481504/000147793222000865/xeri_10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1481504/000147793222000865/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2021-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Research and development | 3 months, 2021-10-01 to 2021-12-31 | $2.9m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2021-07-01 to 2021-12-31 | $5.2m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2021-10-01 to 2021-12-31 | −$4.3m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2021-07-01 to 2021-12-31 | −$8.5m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2021-10-01 to 2021-12-31 | $1.6k | us-gaap:InterestExpense |
| Interest expense | 6 months, 2021-07-01 to 2021-12-31 | $4.0k | us-gaap:InterestExpense |
| Net income | 3 months, 2021-10-01 to 2021-12-31 | −$5.5m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2021-07-01 to 2021-12-31 | −$10.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2021-10-01 to 2021-12-31 | −$0.02 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 6 months, 2021-07-01 to 2021-12-31 | −$6.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2021-07-01 to 2021-12-31 | $5.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2021-12-31 | $2.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2021-12-31 | $2.1m | us-gaap:AssetsCurrent |
| Total assets | at 2021-12-31 | $2.3m | us-gaap:Assets |
| Current liabilities | at 2021-12-31 | $820.5k | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2021-12-31 | $938.1k | us-gaap:Liabilities |
| Shareholders' equity | at 2021-12-31 | $1.3m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 19,065 characters.

*The following discussion of our financial condition and results of operations should be read in conjunction with the audited and unaudited financial statements and the notes to those statements included elsewhere in this Report. This discussion contains forward-looking statements that involve risks and uncertainties. You should specifically consider the various risk factors identified in this Report that could cause actual results to differ materially from those anticipated in these forward-looking statements.*

### Forward-Looking Statements

This Quarterly Report on Form 10-Q contains forward looking statements, including without limitation, statements related to our plans, strategies, objectives, expectations, intentions and adequacy of resources. Investors are cautioned that such forward-looking statements involve risks and uncertainties including without limitation the following: (i) our plans, strategies, objectives, expectations and intentions are subject to change at any time at our discretion; (ii) our plans and results of operations will be affected by our ability to manage growth; and (iii) other risks and uncertainties indicated from time to time in our filings with the Securities and Exchange Commission.

In some cases, you can identify forward-looking statements by terminology such as ‘‘may,’’ ‘‘will,’’ ‘‘should,’’ ‘‘could,’’ ‘‘expects,’’ ‘‘plans,’’ ‘‘intends,’’ ‘‘anticipates,’’ ‘‘believes,’’ ‘‘estimates,’’ ‘‘predicts,’’ ‘‘potential,’’ or ‘‘continue’’ or the negative of such terms or other comparable terminology. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of such statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We are under no duty to update any of the forward-looking statements after the date of this Report.

This section of the report should be read together with Footnotes of the Company audited financials for the year ended June 30, 2021. The unaudited statements of operations for the three and six months ended December 31, 2021 and 2020 are compared in the sections below.

### Brief Corporate History

Xeriant is an aerospace technology and advanced materials holding and operating company focused on Advanced Air Mobility (“AAM”) and the transition to green aerospace. The Company plans to source and acquire complementary and strategic interests in visionary companies developing, integrating, and commercializing critical breakthrough technologies which enhance performance, increase safety, and enable and support more efficient, autonomous, and sustainable flight operations, including electrically powered passenger and cargo transport aircraft capable of vertical takeoff and landing. The Company is located at the Research Park at Florida Atlantic University in Boca Raton, Florida.

The Company was originally incorporated in Nevada on December 18, 2009 under the name Eastern World Solutions, Inc. The name changed to Banjo & Matilda, Inc. on September 24, 2013. Effective June 22, 2020 the Company changed its name from Banjo & Matilda, Inc. to Xeriant, Inc.

On April 16, 2019, the Company entered into a Share Exchange Agreement with American Aviation Technologies, LLC (“AAT”), an aircraft design and development company focused on the emerging segment of the aviation industry of autonomous and semi-autonomous vertical take-off and landing (VTOL) and unmanned aerial vehicles (UAVs).

On June 28, 2019, the Company spun out two wholly owned subsidiaries: Banjo & Matilda (USA), Inc. and Banjo & Matilda Australia Pty LTD.

On September 30, 2019, the acquisition of AAT closed, and AAT became a wholly owned subsidiary of the Company.

On June 22, 2020, the name was changed from Banjo & Matilda, Inc. to Xeriant, Inc.

On May 27, 2021, the Company entered into a Joint Venture Agreement with XTI Aircraft Company, to form a new company, called Eco-Aero, LLC, for purpose of completing the preliminary design of XTI’s TriFan 600, a 5-passenger plus pilot, hybrid electric, vertical takeoff and landing (eVTOL) fixed wing aircraft.

5

#### Table of Contents

On May 31, 2021, the Company entered into a Joint Venture Agreement with XTI Aircraft Company, to form a new company, called Eco-Aero, LLC, for purpose of completing the preliminary design of XTI’s TriFan 600, a 5-passenger plus pilot, hybrid electric, vertical takeoff and landing (eVTOL) fixed wing aircraft.

### Three months ended December 31, 2021 compared to the three months ended December 31, 2020

| Operating expenses: | For the three months ended December 31, 2021 | December 31, 2020 | $% |  |
| --- | ---: | ---: | ---: | ---: |
| Sales and marketing expense | $46,623 | $1,027,109 | $(980,486) | 95% |
| General and administrative expenses | 1,120,250 | 37,469 | 1,082,781 | 2889.80% |
| Professional fees | 102,484 | 14,637 | 87,848 | 600.18% |
| Related party consulting fees | 130,925 | 41,500 | 89,425 | 215.48% |
| Research and development expense | 2,859,644 | - | 2,859,644 | 100% |
| Total operating expenses | 4,259,926 | 1,120,715 | 3,139,211 | 280.11% |
| Loss from operations | (4,259,926) | (1,120,715) | 3,139,211 | 280.11% |
| Other income (expense): |  |  |  |  |
| Amortization of debt discount | (1,264,931) | (66,449) | (1,198,482) | 1,803.61% |
| Amortization of debt discount, related party | - | (3,044) | 3,044 | 100% |
| Interest expense | (1,625) | (1,139) | (486) | 42.67% |
| Interest expense, related parties | - | (46) | (46) | 100% |
| Gain on forgiveness of accounts payable | - | (1,956) | 1,956 | 100% |
| Loss on settlement of debt | (4) | - | (4) | 100% |
| Total other income (expense) | (1,266,560) | (72,634) | (1,193,926) | 1,643.76% |
| Net loss | $(5,526,486) | (1,193,349) | (4,333,137) | 363.11% |

#### Sales and Marketing Expense

Sales and marketing expense was $46,623 for the three months ended December 31, 2021 compared to $1,027,109 for the three months ended December 31, 2020. During the three months ended December 31, 2021, the Company was putting less money into investor relationship to market the Company.

#### General and Administrative Expenses

Total general and administrative expenses were $1,120,250 for the three months ended December 31, 2021 compared to $37,469 for the three months ended December 31, 2020. The increase of $1,082,781 primarily relates to options valued at $827,221 for advisory board services.

#### Professional Fees

Total professional fees were $102,484 for the three months ended December 31, 2021 compared to $14,637 for the three months ended December 31, 2020. The increase of $87,847 primary relates to legal fees.

6

#### Table of Contents

#### Related Party Consulting Fees

Total related party consulting fees were $130,925 for the three months ended December 31, 2021 compared to $41,500 for the three months ended December 31, 2020. The increase of $89,425 was primarily related to $28,000 in new related party expenses coupled with an increase in the pay of existing related party.

#### Research and Development Expenses

Total research and development expenses were $2,859,644 for the three months ended December 31, 2021 compared to $0 for the three months ended December 31, 2020. The research and development costs were mainly related to the development of an aircraft through our Eco-Aero joint venture and $92,746 expenditure to Movychem, a Slovakian limited liability company for research and development in advanced materials and chemicals.

#### Other Expenses

Total other income (expenses) were ($1,266,560) for the three months ended December 31, 2021 compared to ($72,634) for the three months ended December 31, 2020. Total other expenses consist of interest expense on debt, amortization of debt and loss on settlement of debt. The increase of $1,193,926 was primarily related the Company recording amortization of debt discount during the three months ended December 31, 2021 in the amount of $1,264,931.

#### Net loss

Total net loss was $5,526,486 for the three months ended December 30, 2021 compared to $1,193,349 for the three months ended December 31, 2020. The increase of $4,333,137 was primarily due to research and development expenses of $2,766,898 and equity based compensation of $943,326.

### Six months ended December 31, 2021 compared to the six months ended December 31, 2020

| Operating expenses: | For the six months ended December 31, 2021 | December 31, 2020 | $% |  |
| --- | ---: | ---: | ---: | ---: |
| Sales and marketing expense | $645,218 | $1,027,109 | $(381,891) | 37.18% |
| General and administrative expenses | 2,321,252 | 73,439 | 2,247,813 | 3060.79% |
| Professional fees | 132,025 | 35,237 | 96,788 | 274.68% |
| Related party consulting fees | 213,425 | 78,000 | 135,425 | 173.62% |
| Research and development expense | 5,200,219 | - | 5,200,219 | 100% |
| Total operating expenses | 8,512,139 | 1,213,785 | 7,298,354 | 601.29% |
| Loss from operations | (8,512,139) | (1,213,785) | 7,298,354 | 601.29% |
| Other income (expense): |  |  |  |  |
| Amortization of debt discount | (1,413,959) | (112,410) | (1,301,549) | 1,157.86% |
| Amortization of debt discount, related party | - | (5,000) | 5,000 | 100% |
| Financing fees | (43,750) | - | (43,750) | 100% |
| Interest expense | (4,014) | (2,196) | (1,818) | 82.79% |
| Interest expense, related parties | - | (76) | 76 | 100% |
| Loss on settlement of debt | (536) | (186,954) | 186,418 | 99.71% |
| Total other income (expense) | (1,462,259) | (306,636) | (1,155,623) | 376.87% |
| Net loss | $(9,974,398) | (1,520,421) | (8,453,977) | 556.03% |

7

#### Table of Contents

#### Sales and Marketing Expense

Sales and marketing expense was $645,218 for the six months ended December 31, 2021 compared to $1,027,109 for the six months ended December 31, 2020. During the six months ended December 31, 2021, the Company was putting money into sales and marketing expenses to actively market the brand.

#### General and Administrative Expenses

Total general and administrative expenses were $2,321,252 for the six months ended December 31, 2021 compared to $73,439 for the six months ended December 31, 2020. The increase of $2,247,813 primarily relates to options valued at $1,887,545 for advisory board services and $657,204 from stock issued for services.

#### Professional Fees

Total professional fees were $132,025 for the six months ended December 31, 2021 compared to $35,237 for the six months ended December 31, 2020. The increase of $96,789 primary relates to legal fees.

#### Related Party Consulting Fees

Total related party consulting fees were $213,425 for the six months ended December 31, 2021 compared to $78,000 for the six months ended December 31, 2020. The increase of $135,425 was primarily related to $28,000 in new related party expenses coupled an increase in the pay of existing related party.

#### Research and Development Expenses

Total research and development expenses were $5,200,219 for the six months ended December 31, 2021 compared to $0 for the six months ended December 31, 2020. The research and development costs were related to the development of an aircraft through our Eco-Aero joint venture and $142,790 expenditure to Movychem, a Slovakian limited liability company for research and development in advanced materials and chemicals.

#### Other Expenses

Total other income (expenses) were ($1,462,259) for the six months ended December 31, 2021 compared to ($306,636) for the six months ended December 31, 2020. Total other expenses consist of interest expense on debt, amortization of debt and loss on settlement of debt. The increase of $1,155,623 was primarily related the Company recording amortization of debt discount during the six months ended December 31, 2021 in the amount of $1,413,959.

#### Net loss

Total net loss was $9,974,398 for the six months ended December 30, 2021 compared to $1,520,421 for the six months ended December 31, 2020. The increase of $8,453,977 was primarily due to research and development expenses of $5,200,219 and equity based compensation of $2,544,750.

### Liquidity and Capital Resources

### Operating Activities

Cash used in operations of $6,013,001 during the six months ended December 31, 2021 was primarily resulted from the increase cash used in operations resulted from increased expenditures on research and development expense. The Company has a net loss of $9,974,398 during the six months ended December 31, 2021 and offset by non-cash expenses such as stock compensation expense of $1,887,545, stock issued for services of $657,204, and amortization of debt discounts of $1,413,959.

Cash used in operations of $162,557 during the six months ended December 31, 2020 was primarily a result of our $1,520,421 net loss reconciled with our net non-cash expenses relating to amortization of debt discount and our changes in operating assets and liabilities relating to accounts payable and accrued liabilities.

### Investing Activities

Net cash used in investing activities for the six months ended December 31, 2021 was $4,990, which consisted of purchase of new equipment.

### Financing Activities

Net cash provided by financing activities for the six months ended December 31, 2021 was $7,166,000, which consisted of proceeds from the sale of common stock of $2,078,500, cash in the amount of $128,550 from the exercise of warrants, and issuance of convertible debt of $4,958,950.

Net cash provided by financing activities for the six months ended December 31, 2020 was $143,300, which consisted of proceeds from the sale of common stock of $51,000 and issuance of convertible debt of $92,300.

8

#### Table of Contents

The Company’s financial statements are prepared using the generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. At December 31, 2021 and June 30, 2021, the Company had $2,110,549 and $962,540 in cash and $1,305,399 and $677,257 in working capital, respectively. For the six months ended December 31, 2021 and 2020, the Company had a net loss of $9,974,398 and $1,520,421, respectively. Continued losses may adversely affect the liquidity of the Company in the future. Therefore, the factors noted above raise substantial doubt about our ability to continue as a going concern. The recoverability of a major portion of the recorded asset amounts shown in the accompanying balance sheets is dependent upon continued operations of the Company, which in turn is dependent upon the Company’s ability to raise additional capital, obtain financing and to succeed in its future operations. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s existence is dependent upon management’s ability to develop profitable operations and resolve its liquidity problems.

### Commitments for Capital Expenditures

To date, our operations have been funded primarily through private investors. We have had a number of discussions with investment banker and institutional investment, which is to acquire and develop breakthrough technologies or business interests in those companies that have developed these technologies. There is no assurance that the Company will be able to obtain such funding and/or working capital. To the extent that funding is not available, the Company will be required to scale back or discontinue its business plan. Even if the Company is able to obtain financing, it may contain undue restrictions of the Company’s operations, or there may be substantial dilution for our shareholders in the case of equity financing or convertible debt financing.

### Off Balance Sheet Items

We do not have any off-balance sheet arrangements, financings, or other relationships with unconsolidated entities or other persons, also known as “special purpose entities” (SPEs).

### Quantitative and Qualitative Disclosures about Market Risk

In the ordinary course of our business, we are not exposed to market risk of the sort that may arise from changes in interest rates or foreign currency exchange rates, or that may otherwise arise from transactions in derivatives.

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant assumptions and estimates relate to the valuation of beneficial conversion features and warrants associated with convertible debt. Actual results could differ from these estimates.

9

#### Table of Contents

### Contingencies

Certain conditions may exist as of the date the financial statements are issued, which may result in a loss to the Company, but which will only be resolved when one or more future events occur or fail to occur. Our management, in consultation with its legal counsel as appropriate, assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against us or unasserted claims that may result in such proceedings, we, in consultation with legal counsel, evaluates the perceived merits of any legal proceedings or unasserted claims, as well as the perceived merits of the amount of relief sought or expected to be sought therein. If the assessment of a contingency indicates it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in our financial statements. If the assessment indicates a potentially material loss contingency is not probable, but is reasonably possible, or is probable, but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss, if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed.

On September 1, 2021, Xeriant Inc. brought a cause of action in the Southern District of Florida against a former shareholder for claims, including but not limited to, breach of contract, misrepresentation, and asserting claims to recoup monetary and in-kind distributions made to the shareholder by the Company. The defendant in the above-mentioned action has not asserted any counterclaims to-date.

## Controls and procedures

As filed, 1,710 characters.

### Disclosure Controls and Procedures

Our management is responsible for maintaining disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that the Registrant files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. In addition, the disclosure controls and procedures must ensure that such information is accumulated and communicated to the Registrant’s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required financial and other required disclosures.

At December 31, 2021, an evaluation of the effectiveness of our disclosure controls and procedures (as defined in Rules 13(a)-15(e) and 15(d)-15(e) of the Exchange Act) was carried out under the supervision and with the participation of Keith Duffy our Chief Executive Officer and Brian Carey our Chief Financial Officer. Based on his evaluation of our disclosure controls and procedures, he concluded that at December 31, 2021, our disclosure controls and procedures are not effective due to material weaknesses in our internal controls over financial reporting discussed directly below.

### Changes in Internal Control Over Financial Reporting

There has been no change in the Company’s internal control over financial reporting, as defined in Rules 13a-15(f) of the Exchange Act, during the Company’s most recent fiscal quarter ended December 31, 2021, that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

10

#### Table of Contents

## Risk factors

As filed, 157 characters.

Our business is subject to numerous risks and uncertainties including but not limited to those discussed in “Risk Factors” in our Annual Report on Form 10-K.

Filed Feb 15, 2022.
Source: SEC EDGAR, the filing index for accession 0001477932-22-000865. Last ingested by Listed: Oct 24, 2026, 15:08 ET. No prices; not investment advice.
